Influenza vaccine effectiveness in preventing inpatient and outpatient cases in a season dominated by vaccine-matched influenza B virus.
Identifieur interne : 000179 ( Main/Exploration ); précédent : 000178; suivant : 000180Influenza vaccine effectiveness in preventing inpatient and outpatient cases in a season dominated by vaccine-matched influenza B virus.
Auteurs : Iván Martínez-Baz [Espagne] ; Ana Navascués ; Francisco Pozo ; Judith Chamorro ; Esther Albeniz ; Itziar Casado ; Gabriel Reina ; Manuel García Cenoz ; Carmen Ezpeleta ; Jesús CastillaSource :
- Human vaccines & immunotherapeutics [ 2164-554X ] ; 2015.
Descripteurs français
- KwdFr :
- Adolescent (MeSH), Adulte (MeSH), Adulte d'âge moyen (MeSH), Dossiers médicaux électroniques (MeSH), Efficacité du vaccin (MeSH), Enfant (MeSH), Enfant d'âge préscolaire (MeSH), Espagne (épidémiologie), Facteurs temps (MeSH), Femelle (MeSH), Grippe humaine (prévention et contrôle), Grippe humaine (virologie), Grippe humaine (épidémiologie), Humains (MeSH), Jeune adulte (MeSH), Mâle (MeSH), Odds ratio (MeSH), Patients en consultation externe (MeSH), Patients hospitalisés (MeSH), Saisons (MeSH), Sous-type H1N1 du virus de la grippe A (immunologie), Sous-type H3N2 du virus de la grippe A (immunologie), Sujet âgé (MeSH), Surveillance sentinelle (MeSH), Vaccins antigrippaux (immunologie), Virus influenza B (immunologie), Virus influenza B (pathogénicité), Études cas-témoins (MeSH).
- MESH :
- immunologie : Sous-type H1N1 du virus de la grippe A, Sous-type H3N2 du virus de la grippe A, Vaccins antigrippaux, Virus influenza B.
- pathogénicité : Virus influenza B.
- prévention et contrôle : Grippe humaine.
- virologie : Grippe humaine.
- épidémiologie : Espagne, Grippe humaine.
- Adolescent, Adulte, Adulte d'âge moyen, Dossiers médicaux électroniques, Efficacité du vaccin, Enfant, Enfant d'âge préscolaire, Facteurs temps, Femelle, Humains, Jeune adulte, Mâle, Odds ratio, Patients en consultation externe, Patients hospitalisés, Saisons, Sujet âgé, Surveillance sentinelle, Études cas-témoins.
- Wicri :
- geographic : Espagne.
English descriptors
- KwdEn :
- Adolescent (MeSH), Adult (MeSH), Aged (MeSH), Case-Control Studies (MeSH), Child (MeSH), Child, Preschool (MeSH), Electronic Health Records (MeSH), Female (MeSH), Humans (MeSH), Influenza A Virus, H1N1 Subtype (immunology), Influenza A Virus, H3N2 Subtype (immunology), Influenza B virus (immunology), Influenza B virus (pathogenicity), Influenza Vaccines (immunology), Influenza, Human (epidemiology), Influenza, Human (prevention & control), Influenza, Human (virology), Inpatients (MeSH), Male (MeSH), Middle Aged (MeSH), Odds Ratio (MeSH), Outpatients (MeSH), Seasons (MeSH), Sentinel Surveillance (MeSH), Spain (epidemiology), Time Factors (MeSH), Vaccine Potency (MeSH), Young Adult (MeSH).
- MESH :
- chemical , immunology : Influenza Vaccines.
- geographic , epidemiology : Spain.
- epidemiology : Influenza, Human.
- immunology : Influenza A Virus, H1N1 Subtype, Influenza A Virus, H3N2 Subtype, Influenza B virus.
- pathogenicity : Influenza B virus.
- prevention & control : Influenza, Human.
- virology : Influenza, Human.
- Adolescent, Adult, Aged, Case-Control Studies, Child, Child, Preschool, Electronic Health Records, Female, Humans, Inpatients, Male, Middle Aged, Odds Ratio, Outpatients, Seasons, Sentinel Surveillance, Time Factors, Vaccine Potency, Young Adult.
Abstract
Studies that have evaluated the influenza vaccine effectiveness (VE) to prevent laboratory-confirmed influenza B cases are uncommon, and few have analyzed the effect in preventing hospitalized cases. We have evaluated the influenza VE in preventing outpatient and hospitalized cases with laboratory-confirmed influenza in the 2012-2013 season, which was dominated by a vaccine-matched influenza B virus. In the population covered by the Navarra Health Service, all hospitalized patients with influenza-like illness (ILI) and all ILI patients attended by a sentinel network of general practitioners were swabbed for influenza testing, and all were included in a test-negative case-control analysis. VE was calculated as (1-odds ratio) × 100. Among 744 patients tested, 382 (51%) were positive for influenza virus: 70% for influenza B, 24% for A(H1N1)pdm09, and 5% for A(H3N2). The overall estimate of VE in preventing laboratory-confirmed influenza was 63% (95% confidence interval (CI): 34 to 79), 55% (1 to 80) in outpatients and 74% (33 to 90) in hospitalized patients. The VE was 70% (41 to 85) against influenza B and 43% (-45 to 78) against influenza A. The VE against virus B was 87% (52 to 96) in hospitalized patients and 56% in outpatients (-5 to 81). Adjusted comparison of vaccination status between inpatient and outpatient cases with influenza B did not show statistically significant differences (odds ratio: 1.13; p = 0.878). These results suggest a high protective effect of the vaccine in the 2012-2013 season, with no differences found for the effect between outpatient and hospitalized cases.
DOI: 10.1080/21645515.2015.1038002
PubMed: 25996366
PubMed Central: PMC4514388
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Influenza vaccine effectiveness in preventing inpatient and outpatient cases in a season dominated by vaccine-matched influenza B virus.</title>
<author><name sortKey="Martinez Baz, Ivan" sort="Martinez Baz, Ivan" uniqKey="Martinez Baz I" first="Iván" last="Martínez-Baz">Iván Martínez-Baz</name>
<affiliation wicri:level="1"><nlm:affiliation>a Instituto de Salud Pública de Navarra ; Pamplona , Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>a Instituto de Salud Pública de Navarra ; Pamplona </wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Navascues, Ana" sort="Navascues, Ana" uniqKey="Navascues A" first="Ana" last="Navascués">Ana Navascués</name>
</author>
<author><name sortKey="Pozo, Francisco" sort="Pozo, Francisco" uniqKey="Pozo F" first="Francisco" last="Pozo">Francisco Pozo</name>
</author>
<author><name sortKey="Chamorro, Judith" sort="Chamorro, Judith" uniqKey="Chamorro J" first="Judith" last="Chamorro">Judith Chamorro</name>
</author>
<author><name sortKey="Albeniz, Esther" sort="Albeniz, Esther" uniqKey="Albeniz E" first="Esther" last="Albeniz">Esther Albeniz</name>
</author>
<author><name sortKey="Casado, Itziar" sort="Casado, Itziar" uniqKey="Casado I" first="Itziar" last="Casado">Itziar Casado</name>
</author>
<author><name sortKey="Reina, Gabriel" sort="Reina, Gabriel" uniqKey="Reina G" first="Gabriel" last="Reina">Gabriel Reina</name>
</author>
<author><name sortKey="Cenoz, Manuel Garcia" sort="Cenoz, Manuel Garcia" uniqKey="Cenoz M" first="Manuel García" last="Cenoz">Manuel García Cenoz</name>
</author>
<author><name sortKey="Ezpeleta, Carmen" sort="Ezpeleta, Carmen" uniqKey="Ezpeleta C" first="Carmen" last="Ezpeleta">Carmen Ezpeleta</name>
</author>
<author><name sortKey="Castilla, Jesus" sort="Castilla, Jesus" uniqKey="Castilla J" first="Jesús" last="Castilla">Jesús Castilla</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2015">2015</date>
<idno type="RBID">pubmed:25996366</idno>
<idno type="pmid">25996366</idno>
<idno type="doi">10.1080/21645515.2015.1038002</idno>
<idno type="pmc">PMC4514388</idno>
<idno type="wicri:Area/Main/Corpus">00171</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">00171</idno>
<idno type="wicri:Area/Main/Curation">000171</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000171</idno>
<idno type="wicri:Area/Main/Exploration">000171</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Influenza vaccine effectiveness in preventing inpatient and outpatient cases in a season dominated by vaccine-matched influenza B virus.</title>
<author><name sortKey="Martinez Baz, Ivan" sort="Martinez Baz, Ivan" uniqKey="Martinez Baz I" first="Iván" last="Martínez-Baz">Iván Martínez-Baz</name>
<affiliation wicri:level="1"><nlm:affiliation>a Instituto de Salud Pública de Navarra ; Pamplona , Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>a Instituto de Salud Pública de Navarra ; Pamplona </wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Navascues, Ana" sort="Navascues, Ana" uniqKey="Navascues A" first="Ana" last="Navascués">Ana Navascués</name>
</author>
<author><name sortKey="Pozo, Francisco" sort="Pozo, Francisco" uniqKey="Pozo F" first="Francisco" last="Pozo">Francisco Pozo</name>
</author>
<author><name sortKey="Chamorro, Judith" sort="Chamorro, Judith" uniqKey="Chamorro J" first="Judith" last="Chamorro">Judith Chamorro</name>
</author>
<author><name sortKey="Albeniz, Esther" sort="Albeniz, Esther" uniqKey="Albeniz E" first="Esther" last="Albeniz">Esther Albeniz</name>
</author>
<author><name sortKey="Casado, Itziar" sort="Casado, Itziar" uniqKey="Casado I" first="Itziar" last="Casado">Itziar Casado</name>
</author>
<author><name sortKey="Reina, Gabriel" sort="Reina, Gabriel" uniqKey="Reina G" first="Gabriel" last="Reina">Gabriel Reina</name>
</author>
<author><name sortKey="Cenoz, Manuel Garcia" sort="Cenoz, Manuel Garcia" uniqKey="Cenoz M" first="Manuel García" last="Cenoz">Manuel García Cenoz</name>
</author>
<author><name sortKey="Ezpeleta, Carmen" sort="Ezpeleta, Carmen" uniqKey="Ezpeleta C" first="Carmen" last="Ezpeleta">Carmen Ezpeleta</name>
</author>
<author><name sortKey="Castilla, Jesus" sort="Castilla, Jesus" uniqKey="Castilla J" first="Jesús" last="Castilla">Jesús Castilla</name>
</author>
</analytic>
<series><title level="j">Human vaccines & immunotherapeutics</title>
<idno type="eISSN">2164-554X</idno>
<imprint><date when="2015" type="published">2015</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent (MeSH)</term>
<term>Adult (MeSH)</term>
<term>Aged (MeSH)</term>
<term>Case-Control Studies (MeSH)</term>
<term>Child (MeSH)</term>
<term>Child, Preschool (MeSH)</term>
<term>Electronic Health Records (MeSH)</term>
<term>Female (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Influenza A Virus, H1N1 Subtype (immunology)</term>
<term>Influenza A Virus, H3N2 Subtype (immunology)</term>
<term>Influenza B virus (immunology)</term>
<term>Influenza B virus (pathogenicity)</term>
<term>Influenza Vaccines (immunology)</term>
<term>Influenza, Human (epidemiology)</term>
<term>Influenza, Human (prevention & control)</term>
<term>Influenza, Human (virology)</term>
<term>Inpatients (MeSH)</term>
<term>Male (MeSH)</term>
<term>Middle Aged (MeSH)</term>
<term>Odds Ratio (MeSH)</term>
<term>Outpatients (MeSH)</term>
<term>Seasons (MeSH)</term>
<term>Sentinel Surveillance (MeSH)</term>
<term>Spain (epidemiology)</term>
<term>Time Factors (MeSH)</term>
<term>Vaccine Potency (MeSH)</term>
<term>Young Adult (MeSH)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent (MeSH)</term>
<term>Adulte (MeSH)</term>
<term>Adulte d'âge moyen (MeSH)</term>
<term>Dossiers médicaux électroniques (MeSH)</term>
<term>Efficacité du vaccin (MeSH)</term>
<term>Enfant (MeSH)</term>
<term>Enfant d'âge préscolaire (MeSH)</term>
<term>Espagne (épidémiologie)</term>
<term>Facteurs temps (MeSH)</term>
<term>Femelle (MeSH)</term>
<term>Grippe humaine (prévention et contrôle)</term>
<term>Grippe humaine (virologie)</term>
<term>Grippe humaine (épidémiologie)</term>
<term>Humains (MeSH)</term>
<term>Jeune adulte (MeSH)</term>
<term>Mâle (MeSH)</term>
<term>Odds ratio (MeSH)</term>
<term>Patients en consultation externe (MeSH)</term>
<term>Patients hospitalisés (MeSH)</term>
<term>Saisons (MeSH)</term>
<term>Sous-type H1N1 du virus de la grippe A (immunologie)</term>
<term>Sous-type H3N2 du virus de la grippe A (immunologie)</term>
<term>Sujet âgé (MeSH)</term>
<term>Surveillance sentinelle (MeSH)</term>
<term>Vaccins antigrippaux (immunologie)</term>
<term>Virus influenza B (immunologie)</term>
<term>Virus influenza B (pathogénicité)</term>
<term>Études cas-témoins (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Influenza Vaccines</term>
</keywords>
<keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Spain</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Sous-type H1N1 du virus de la grippe A</term>
<term>Sous-type H3N2 du virus de la grippe A</term>
<term>Vaccins antigrippaux</term>
<term>Virus influenza B</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term>
<term>Influenza A Virus, H3N2 Subtype</term>
<term>Influenza B virus</term>
</keywords>
<keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>Influenza B virus</term>
</keywords>
<keywords scheme="MESH" qualifier="pathogénicité" xml:lang="fr"><term>Virus influenza B</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Grippe humaine</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Grippe humaine</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Espagne</term>
<term>Grippe humaine</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Aged</term>
<term>Case-Control Studies</term>
<term>Child</term>
<term>Child, Preschool</term>
<term>Electronic Health Records</term>
<term>Female</term>
<term>Humans</term>
<term>Inpatients</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Odds Ratio</term>
<term>Outpatients</term>
<term>Seasons</term>
<term>Sentinel Surveillance</term>
<term>Time Factors</term>
<term>Vaccine Potency</term>
<term>Young Adult</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term>
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Dossiers médicaux électroniques</term>
<term>Efficacité du vaccin</term>
<term>Enfant</term>
<term>Enfant d'âge préscolaire</term>
<term>Facteurs temps</term>
<term>Femelle</term>
<term>Humains</term>
<term>Jeune adulte</term>
<term>Mâle</term>
<term>Odds ratio</term>
<term>Patients en consultation externe</term>
<term>Patients hospitalisés</term>
<term>Saisons</term>
<term>Sujet âgé</term>
<term>Surveillance sentinelle</term>
<term>Études cas-témoins</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Espagne</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Studies that have evaluated the influenza vaccine effectiveness (VE) to prevent laboratory-confirmed influenza B cases are uncommon, and few have analyzed the effect in preventing hospitalized cases. We have evaluated the influenza VE in preventing outpatient and hospitalized cases with laboratory-confirmed influenza in the 2012-2013 season, which was dominated by a vaccine-matched influenza B virus. In the population covered by the Navarra Health Service, all hospitalized patients with influenza-like illness (ILI) and all ILI patients attended by a sentinel network of general practitioners were swabbed for influenza testing, and all were included in a test-negative case-control analysis. VE was calculated as (1-odds ratio) × 100. Among 744 patients tested, 382 (51%) were positive for influenza virus: 70% for influenza B, 24% for A(H1N1)pdm09, and 5% for A(H3N2). The overall estimate of VE in preventing laboratory-confirmed influenza was 63% (95% confidence interval (CI): 34 to 79), 55% (1 to 80) in outpatients and 74% (33 to 90) in hospitalized patients. The VE was 70% (41 to 85) against influenza B and 43% (-45 to 78) against influenza A. The VE against virus B was 87% (52 to 96) in hospitalized patients and 56% in outpatients (-5 to 81). Adjusted comparison of vaccination status between inpatient and outpatient cases with influenza B did not show statistically significant differences (odds ratio: 1.13; p = 0.878). These results suggest a high protective effect of the vaccine in the 2012-2013 season, with no differences found for the effect between outpatient and hospitalized cases.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25996366</PMID>
<DateCompleted><Year>2016</Year>
<Month>05</Month>
<Day>09</Day>
</DateCompleted>
<DateRevised><Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2164-554X</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>11</Volume>
<Issue>7</Issue>
<PubDate><Year>2015</Year>
</PubDate>
</JournalIssue>
<Title>Human vaccines & immunotherapeutics</Title>
<ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation>
</Journal>
<ArticleTitle>Influenza vaccine effectiveness in preventing inpatient and outpatient cases in a season dominated by vaccine-matched influenza B virus.</ArticleTitle>
<Pagination><MedlinePgn>1626-33</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1080/21645515.2015.1038002</ELocationID>
<Abstract><AbstractText>Studies that have evaluated the influenza vaccine effectiveness (VE) to prevent laboratory-confirmed influenza B cases are uncommon, and few have analyzed the effect in preventing hospitalized cases. We have evaluated the influenza VE in preventing outpatient and hospitalized cases with laboratory-confirmed influenza in the 2012-2013 season, which was dominated by a vaccine-matched influenza B virus. In the population covered by the Navarra Health Service, all hospitalized patients with influenza-like illness (ILI) and all ILI patients attended by a sentinel network of general practitioners were swabbed for influenza testing, and all were included in a test-negative case-control analysis. VE was calculated as (1-odds ratio) × 100. Among 744 patients tested, 382 (51%) were positive for influenza virus: 70% for influenza B, 24% for A(H1N1)pdm09, and 5% for A(H3N2). The overall estimate of VE in preventing laboratory-confirmed influenza was 63% (95% confidence interval (CI): 34 to 79), 55% (1 to 80) in outpatients and 74% (33 to 90) in hospitalized patients. The VE was 70% (41 to 85) against influenza B and 43% (-45 to 78) against influenza A. The VE against virus B was 87% (52 to 96) in hospitalized patients and 56% in outpatients (-5 to 81). Adjusted comparison of vaccination status between inpatient and outpatient cases with influenza B did not show statistically significant differences (odds ratio: 1.13; p = 0.878). These results suggest a high protective effect of the vaccine in the 2012-2013 season, with no differences found for the effect between outpatient and hospitalized cases.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Martínez-Baz</LastName>
<ForeName>Iván</ForeName>
<Initials>I</Initials>
<AffiliationInfo><Affiliation>a Instituto de Salud Pública de Navarra ; Pamplona , Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Navascués</LastName>
<ForeName>Ana</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y"><LastName>Pozo</LastName>
<ForeName>Francisco</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y"><LastName>Chamorro</LastName>
<ForeName>Judith</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y"><LastName>Albeniz</LastName>
<ForeName>Esther</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y"><LastName>Casado</LastName>
<ForeName>Itziar</ForeName>
<Initials>I</Initials>
</Author>
<Author ValidYN="Y"><LastName>Reina</LastName>
<ForeName>Gabriel</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y"><LastName>Cenoz</LastName>
<ForeName>Manuel García</ForeName>
<Initials>MG</Initials>
</Author>
<Author ValidYN="Y"><LastName>Ezpeleta</LastName>
<ForeName>Carmen</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y"><LastName>Castilla</LastName>
<ForeName>Jesús</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y"><CollectiveName>Primary Health Care Sentinel Network and Network for Influenza Surveillance in Hospitals of Navarra</CollectiveName>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Hum Vaccin Immunother</MedlineTA>
<NlmUniqueID>101572652</NlmUniqueID>
<ISSNLinking>2164-5515</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053118" MajorTopicYN="N">Influenza A Virus, H1N1 Subtype</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053122" MajorTopicYN="N">Influenza A Virus, H3N2 Subtype</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009981" MajorTopicYN="Y">Influenza B virus</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007297" MajorTopicYN="N">Inpatients</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016017" MajorTopicYN="N">Odds Ratio</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010045" MajorTopicYN="N">Outpatients</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012621" MajorTopicYN="N">Seasons</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018571" MajorTopicYN="N">Sentinel Surveillance</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N" Type="Geographic">Spain</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D064166" MajorTopicYN="N">Vaccine Potency</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CI, confidence interval</Keyword>
<Keyword MajorTopicYN="N">ILI, influenza-like illness</Keyword>
<Keyword MajorTopicYN="N">OR, odds ratio</Keyword>
<Keyword MajorTopicYN="N">RT-PCR, reverse transcription polymerase chain reaction</Keyword>
<Keyword MajorTopicYN="N">VE, vaccine effectiveness</Keyword>
<Keyword MajorTopicYN="N">case-control study</Keyword>
<Keyword MajorTopicYN="N">effectiveness</Keyword>
<Keyword MajorTopicYN="N">influenza</Keyword>
<Keyword MajorTopicYN="N">influenza B virus</Keyword>
<Keyword MajorTopicYN="N">influenza vaccine</Keyword>
<Keyword MajorTopicYN="N">sentinel surveillance</Keyword>
</KeywordList>
<InvestigatorList><Investigator ValidYN="Y"><LastName>Abad</LastName>
<ForeName>I</ForeName>
<Initials>I</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Aldaz</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Álvarez</LastName>
<ForeName>E</ForeName>
<Initials>E</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Arana</LastName>
<ForeName>J J</ForeName>
<Initials>JJ</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Arceiz</LastName>
<ForeName>I</ForeName>
<Initials>I</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Arina</LastName>
<ForeName>E</ForeName>
<Initials>E</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Arribas</LastName>
<ForeName>I</ForeName>
<Initials>I</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Artajo</LastName>
<ForeName>M D</ForeName>
<Initials>MD</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Arza</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Azagra</LastName>
<ForeName>B</ForeName>
<Initials>B</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Bartolome</LastName>
<ForeName>F C</ForeName>
<Initials>FC</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Bernués</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Bolea</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Brugos</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Cano</LastName>
<ForeName>B</ForeName>
<Initials>B</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Castresana</LastName>
<ForeName>M V</ForeName>
<Initials>MV</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Cenoz</LastName>
<ForeName>J C</ForeName>
<Initials>JC</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Cia</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Compains</LastName>
<ForeName>B</ForeName>
<Initials>B</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Corpas</LastName>
<ForeName>J R</ForeName>
<Initials>JR</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Cortés</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Churío</LastName>
<ForeName>B</ForeName>
<Initials>B</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Cuevas</LastName>
<ForeName>P C</ForeName>
<Initials>PC</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Da Costa</LastName>
<ForeName>E M</ForeName>
<Initials>EM</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Díez Espino</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Doiz</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Escribano</LastName>
<ForeName>F J</ForeName>
<Initials>FJ</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Esparza</LastName>
<ForeName>M J</ForeName>
<Initials>MJ</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Etayo</LastName>
<ForeName>V</ForeName>
<Initials>V</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Fernández Alfaro</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Flamarique</LastName>
<ForeName>B</ForeName>
<Initials>B</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Gamboa</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Garcés</LastName>
<ForeName>M L</ForeName>
<Initials>ML</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>García Blanco</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>German</LastName>
<ForeName>A B</ForeName>
<Initials>AB</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Giner</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Gómara</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Goñi</LastName>
<ForeName>N</ForeName>
<Initials>N</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Guillorme</LastName>
<ForeName>M J</ForeName>
<Initials>MJ</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Guiu</LastName>
<ForeName>J O</ForeName>
<Initials>JO</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Gurbindo</LastName>
<ForeName>J C</ForeName>
<Initials>JC</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Guruchaga</LastName>
<ForeName>M J</ForeName>
<Initials>MJ</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Heras</LastName>
<ForeName>J A</ForeName>
<Initials>JA</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Hijos</LastName>
<ForeName>M C</ForeName>
<Initials>MC</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Indurain</LastName>
<ForeName>M S</ForeName>
<Initials>MS</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Iñigo</LastName>
<ForeName>B</ForeName>
<Initials>B</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Juan Belloc</LastName>
<ForeName>S E</ForeName>
<Initials>SE</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Jurio</LastName>
<ForeName>J J</ForeName>
<Initials>JJ</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>León</LastName>
<ForeName>M P</ForeName>
<Initials>MP</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Longás</LastName>
<ForeName>J J</ForeName>
<Initials>JJ</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Miner</LastName>
<ForeName>J J</ForeName>
<Initials>JJ</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Moreno</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Moros</LastName>
<ForeName>M A</ForeName>
<Initials>MA</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Navarro</LastName>
<ForeName>U</ForeName>
<Initials>U</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Orozco</LastName>
<ForeName>F J</ForeName>
<Initials>FJ</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Orte</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Palacio</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Palau</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Pérez Lecumberri</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Pérez Pascual</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Pérez Sanz</LastName>
<ForeName>B</ForeName>
<Initials>B</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Prado Virto</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Prado Santamaria</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Puig Arrastia</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Ridruejo</LastName>
<ForeName>E</ForeName>
<Initials>E</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Ramos</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Rípodas</LastName>
<ForeName>B E</ForeName>
<Initials>BE</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Rodríguez</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Roncal</LastName>
<ForeName>M A</ForeName>
<Initials>MA</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Ruiz Puertas</LastName>
<ForeName>I</ForeName>
<Initials>I</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Sánchez Vázquez</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Sarrasqueta</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Senosiain</LastName>
<ForeName>M A</ForeName>
<Initials>MA</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Sola</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Sota</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Ursua</LastName>
<ForeName>M E</ForeName>
<Initials>ME</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Urtasun</LastName>
<ForeName>I A</ForeName>
<Initials>IA</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Vigata</LastName>
<ForeName>M J</ForeName>
<Initials>MJ</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Virto</LastName>
<ForeName>M T</ForeName>
<Initials>MT</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Vizcay</LastName>
<ForeName>J M</ForeName>
<Initials>JM</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Artajo</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Beristain</LastName>
<ForeName>X</ForeName>
<Initials>X</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Bernaola</LastName>
<ForeName>E</ForeName>
<Initials>E</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Chamorro</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Esquiroz</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Fanlo</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Gil</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Gabari</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Hueto</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Martín</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Peña</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Pérez</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Ruiz</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Fernández-Alonso</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Núñez</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>García Irure</LastName>
<ForeName>J J</ForeName>
<Initials>JJ</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Torres</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Ortega</LastName>
<ForeName>M T</ForeName>
<Initials>MT</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Lameiro</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Barrado</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Alvarez</LastName>
<ForeName>N</ForeName>
<Initials>N</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Guevara</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Irisarri</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Arriazu</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Zabala</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Barricarte</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Castilla</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Investigator>
</InvestigatorList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year>
<Month>5</Month>
<Day>22</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2015</Year>
<Month>5</Month>
<Day>23</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2016</Year>
<Month>5</Month>
<Day>10</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">25996366</ArticleId>
<ArticleId IdType="doi">10.1080/21645515.2015.1038002</ArticleId>
<ArticleId IdType="pmc">PMC4514388</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Euro Surveill. 2012;17(17). pii: 20154</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22551499</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Wkly Epidemiol Rec. 2012 Mar 9;87(10):83-95</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22462202</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Euro Surveill. 2013;18(5). pii: 20388</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23399423</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2013 Feb 14;368(7):589-92</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23343038</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Euro Surveill. 2013;18(7):2</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23449182</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2013;8(3):e58222</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23472161</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMC Public Health. 2013;13:191</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23496887</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2013 Jun 26;31(30):3104-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23624093</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2014;9(3):e92153</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24667168</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Euro Surveill. 2014;19(6). pii: 20701</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24556348</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Euro Surveill. 2013;18(37). pii: 20585</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24079398</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2014;9(6):e100497</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24945510</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Epidemiol Infect. 2014 Sep;142(9):1809-12</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24814635</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2014 Nov 15;59(10):1375-85</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25270645</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2014 Dec 1;59(11):1519-24</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25139969</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Euro Surveill. 2015;20(2). pii: 21011</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25613779</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Hum Vaccin Immunother. 2015;11(1):225-30</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25483540</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2015 May 15;211(10):1529-40</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25406334</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Epidemiol. 2006 Apr;35(2):337-44</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16368725</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2007 Oct 4;357(14):1373-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17914038</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2009 Jan 15;199(2):168-79</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19086914</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2010 Feb 25;28(9):2149-56</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20003926</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2010 Sep 7;28 Suppl 4:D45-53</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20713260</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2010 Oct 28;28(46):7381-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20851086</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Infect Dis. 2012 Jan;12(1):36-44</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22032844</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2012 Jan 5;30(2):195-200</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22100636</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2012 Mar 2;30(11):1993-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22226861</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Public Health. 2013 Mar;103(3):e43-51</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23327249</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Espagne</li>
</country>
</list>
<tree><noCountry><name sortKey="Albeniz, Esther" sort="Albeniz, Esther" uniqKey="Albeniz E" first="Esther" last="Albeniz">Esther Albeniz</name>
<name sortKey="Casado, Itziar" sort="Casado, Itziar" uniqKey="Casado I" first="Itziar" last="Casado">Itziar Casado</name>
<name sortKey="Castilla, Jesus" sort="Castilla, Jesus" uniqKey="Castilla J" first="Jesús" last="Castilla">Jesús Castilla</name>
<name sortKey="Cenoz, Manuel Garcia" sort="Cenoz, Manuel Garcia" uniqKey="Cenoz M" first="Manuel García" last="Cenoz">Manuel García Cenoz</name>
<name sortKey="Chamorro, Judith" sort="Chamorro, Judith" uniqKey="Chamorro J" first="Judith" last="Chamorro">Judith Chamorro</name>
<name sortKey="Ezpeleta, Carmen" sort="Ezpeleta, Carmen" uniqKey="Ezpeleta C" first="Carmen" last="Ezpeleta">Carmen Ezpeleta</name>
<name sortKey="Navascues, Ana" sort="Navascues, Ana" uniqKey="Navascues A" first="Ana" last="Navascués">Ana Navascués</name>
<name sortKey="Pozo, Francisco" sort="Pozo, Francisco" uniqKey="Pozo F" first="Francisco" last="Pozo">Francisco Pozo</name>
<name sortKey="Reina, Gabriel" sort="Reina, Gabriel" uniqKey="Reina G" first="Gabriel" last="Reina">Gabriel Reina</name>
</noCountry>
<country name="Espagne"><noRegion><name sortKey="Martinez Baz, Ivan" sort="Martinez Baz, Ivan" uniqKey="Martinez Baz I" first="Iván" last="Martínez-Baz">Iván Martínez-Baz</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeEspagneV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000179 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000179 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= GrippeEspagneV1 |flux= Main |étape= Exploration |type= RBID |clé= pubmed:25996366 |texte= Influenza vaccine effectiveness in preventing inpatient and outpatient cases in a season dominated by vaccine-matched influenza B virus. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:25996366" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \ | NlmPubMed2Wicri -a GrippeEspagneV1
This area was generated with Dilib version V0.6.37. |